GE HealthCare has a credible earnings delivery track record — three beats in the prior three quarters before the most recent miss — and a favorable risk/reward of roughly 2.1-to-1 with approximately 11% room to the analyst-derived target, but the stock is in a confirmed technical downtrend with a death cross in place and growth is soft, making the setup one that rewards patience until the chart stabilizes.
Thesis pillars
- Earnings Delivery Record↓Deteriorating
- Confirmed Technical Downtrend→Stable
- Favorable Risk Reward Setup↑Improving
- +2 more pillars — see the Why tab for full reasoning
GE HealthCare Technologies Inc. (GEHC) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $60.88 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 4 days (event risk); Weak growth.
GE HealthCare Technologies manufactures medical imaging systems (CT, MR, X-ray, ultrasound, molecular imaging), patient monitoring devices, and pharmaceutical diagnostic agents — contrast media and radiopharmaceuticals — sold to hospitals and health systems in over 160 countries... Read more
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $60.88 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 4 days (event risk); Weak growth. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Score 5.4/10, moderate confidence.
Passes 4/8 gates (favorable risk/reward ratio, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and no CEO selling and death cross (50MA < 200MA) and earnings proximity 4d<=7d. Suitability: moderate.
Recent developments
updated 2026-07-26Recent Developments — GE HealthCare Technologies Inc.
Latest news
- NEWS GE HealthCare Stock Sinks After Earnings. It’s Lagging Behind the Other Two GEs. - Barron's — Barron's negative
- NEWS GE HealthCare Technologies Stock (GEHC) Opinions on Q1 Earnings Miss and Guidance Cut - Quiver Quantitative — Quiver Quantitative negative
- NEWS Stocks making the biggest moves midday: GE HealthCare Technologies, Bloom Energy, Seagate, Teradyne, & more - CNBC — CNBC neutral
- NEWS GE HealthCare stock falls on guidance cut (GEHC:NASDAQ) - Seeking Alpha — Seeking Alpha negative
- NEWS GE HealthCare (GEHC) Stock Falls After Earnings Miss and Guidance Cut - MEXC — MEXC negative
Generated 2026-07-26T09:23:00Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicoutside the U.S.10-K Item 1A: 'We generate the majority of our revenue outside of the U.S.'
Material Events(8-K, last 90d)
- 2026-03-17Item 5.02LOWKevin A. Lobo appointed to GE HealthCare Board of Directors and Talent, Culture, and Compensation Committee, effective March 13, 2026. New board appointment; no director departed. No arrangement with any other person cited as basis for selection.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $60.88 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Earnings in 4 days (event risk); Weak growth. Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Prior stop was $58.39. Score 5.4/10, moderate confidence.
Take-profit target: $71.40 (+17.9% upside). Prior stop was $58.39. Stop-loss: $58.39.
Earnings in 4 days (event risk); Weak growth; Negative momentum.
GE HealthCare Technologies Inc. trades at a P/E of 14.8 (forward 11.3). TrendMatrix value score: 7.4/10. Verdict: Sell.
28 analysts cover GEHC with a consensus score of 4.0/5. Average price target: $79.
What does GE HealthCare Technologies Inc. do?GE HealthCare Technologies manufactures medical imaging systems (CT, MR, X-ray, ultrasound, molecular imaging), patient...
GE HealthCare Technologies manufactures medical imaging systems (CT, MR, X-ray, ultrasound, molecular imaging), patient monitoring devices, and pharmaceutical diagnostic agents — contrast media and radiopharmaceuticals — sold to hospitals and health systems in over 160 countries across four segments. Revenue comes from equipment sales, service contracts, consumables, and AI-enabled software, supported by approximately 54,000 employees with 32% in the United States.